Castleark Management’s 10x Genomics TXG Stock Holding History

Castleark Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-61,310	Closed	-$3.42M	–	316
2023 Q2	$3.42M	Buy	+61,310	New	+$3.32M	0.16%	140

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Castleark Management's TXG Position: Q3 2023 in Review

Castleark Management sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 61,310 shares — an estimated $3.42M sold.

Castleark Management first reported a position in TXG in Q2 2023 and held it in 1 quarter. The position peaked at $3.42M in Q2 2023. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

Castleark Management reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
Castleark Management sold 61,310 10x Genomics shares in Q3 2023, an estimated $3.42M.
Castleark Management first reported a position in 10x Genomics in Q2 2023 and held it in 1 quarter.
Castleark Management's 10x Genomics position peaked at $3.42M in Q2 2023.
256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Castleark Management's 13F filing for Q3 2023, filed 15 Nov 2023.